

NEWS RELEASE

Solasia Announces Summary of SP-04 PledOx[®] Development Status

TOKYO, JAPAN, September 5th, 2022 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today regarding SP-04 PledOx[®] development status.

The results of the non-clinical study conducted since 2021 at the University of Milan, Italy, using a rat model of Taxane-induced peripheral neuropathy are now available, and we have evaluated the results with Egetis Therapeutics AB, the licensor of SP-04 PledOx[®], and Professor Cavaletti of the University of Milan, who was responsible for conducting the study.

The results of the study suggest that SP-04 PledOx[®] may have protective effect on Taxane-induced peripheral neuropathy in terms of the evaluation of some of the parameters predefined in the study protocol. On the other hand, other parameters did not show the same results, and the overall interpretation of the study result was complicated and did not confirm a clear protective effect on the onset of Taxane-induced peripheral neuropathy.

A new animal study will be planned based on the useful information suggested by this study.

###

(Contact)

Solasia Pharma K.K.

Toyokazu Ohata, Public Relations and Investor Relations

Tel: +81 3 5843 8046 (TOKYO)

info@solasia.co.jp

Disclaimer:

The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of the Company. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting the Company's actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. Information contained in this press release is for informational purposes only and should not be considered as investment solicitation. Information with regard to pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice. We do not have any obligation to update or revise any information in this press release, and any update or revision may occur anytime without notice.